China's only Nasdaq-listed cell therapy biotech firm lands in Pudong New Area
The Cellular Biomedicine Group (CBMG), China's only cell therapy biotech company listed on Nasdaq, located its headquarters in Zhangjiang Drug Valley, Pudong New Area of Shanghai, on Nov 4.
The company, having immune cell therapy technology and stem cell therapy technology, will further advance its innovation and application of cell therapy after landing in Zhangjiang.
Liu Bizuo, CEO of CBMG, said that the company will use high-yield, automatic and enclosed cell culture system and integrated chemistry, manufacturing and control (CMC) techniques to produce plasmid vectors and virus vectors, which will be conducive to satisfying the increasing need of drugs in current and future CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) clinical research.
CAR-T, regarded as ultimate therapy for cancer, has proven to be of significant efficacy for blood cancers in clinical experiment. Authoritative overseas institutions predicted global cell therapy sales market is expected to reach hundreds of billions of dollars when cell therapies are used in fields such as regenerative medicine, oncotherapy, and senile diseases and proven effective.
CBMG is building new workshops in Zhangjiang and expanding its GMP (Good Manufacturing Practice) workshops in Wuxi and Beijing, combining a total of 6,500 square meters.
The workshops are used for R&D and production and are able to support the company's simultaneous clinical tests of multiple CAR-T and stem cell candidate drugs.
Liu said that the maximum annual output of the facilities can support the treatment of 10,000 cancer patients and 10,000 knee osteoarthritis patients.
The Zhangjiang Biotech and Pharmaceutical Industrial Base, also known as Zhangjiang Drug Valley, was established in 1994 in the Zhangjiang Hi-Tech Park. With more than 40 research centers, nearly 100 public service platforms and more than 400 innovative enterprises, organizations and institutes, the base has become one of the most innovative and competitive new drug development facilities achieving the most significant innovation results across the country.
The Cellular Biomedicine Group, China's only cell therapy biotech company listed on Nasdaq, locates its headquarters in Zhangjiang Drug Valley, Pudong New Area of Shanghai, on Nov 4. [Photo/WeChat account: zjpark]